Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-8 of 8
  • previous
  • 1
  • next
Item hits:
Issue DateTitleAuthor(s)
20-May-2015Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignanciesBlagden, SP; Rizzuto, I; Stavraka, C; O'Shea, D; Suppiah, P, et al
20-May-2015A first in human Phase I/II study of NUC-1031 in patients with advanced gynecological cancersBlagden, SP; Rizzuto, I; Stavraka, C; O'Shea, D; Suppiah, P, et al
23-Mar-2015The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinomaStronach, EA; Cunnea, P; Turner, C; Guney, T; Aiyappa, R, et al
20-May-2015Homologous recombination (HR) deficiency, tumor BRCA1/2 mutations (tmBRCA) and association with response and outcome following platinum monotherapy in high grade serous ovarian cancer (HGSOC).Brown, R; Timms, K; Paul, J; Hughes, E; El-Bahrawy, M, et al
3-May-2018Biomarker assessment of HR deficiency, tumor BRCA1/2 mutations and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapyStronach, EA; Paul, J; Timms, KM; Hughes, E; Brown, K, et al
3-Aug-2017The tumor suppressor protein OPCML potentiates anti-EGFR and anti-HER2 targeted therapy in HER2-positive ovarian and breast cancer.Zanini, E; Louis, LS; Antony, J; Karali, E; Okon, IS, et al
12-Jan-2016Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopyKyriakides, M; Rama, N; Sidhu, J; Gabra, H; Keun, HC, et al
2-Oct-2018Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I studyBlagden, SP; Rizzuto, I; Suppiah, P; O'Shea, D; Patel, M, et al